The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1138
ISSUE1138
September 2, 2002
Gefitinib (Iressa) for advanced non-small cell lung cancer
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Gefitinib (Iressa) for advanced non-small cell lung cancer
September 2, 2002 (Issue: 1138)
Patients with lung cancer may be asking their physicians about gefitinib (ge fi' tye nib; ZD1839; Iressa -- AstraZeneca), because it has been the subject of positive coverage in the media. An inhibitor of the epidermal growth factor receptor (EGFR)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.